CYPH

Cypherpunk Technologies Inc

May 15 • 04:00PM ET

1.09

-0.12 -9.58 %

Healthcare • Biotechnology • USA • Micro • NASD

May 14, 10:46 AMCypherpunk Technologies reports Q1 2026 results with non-GAAP EPS $-0.46 and discloses new $5M Zcash investment in SEC filing

Peers: ATRA KPTI LCTX TNYA GOSS

| Held by: VTI VXF PINK

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.02	Insider Own	19.26%	Shs Outstand	93.93M	Perf Week	-8.82%
Market Cap	97.63M	Forward P/E	-	EPS next Y	-	Insider Trans	-8.81%	Shs Float	72.65M	Perf Month	20.82%
Enterprise Value	90.98M	PEG	-	EPS next Q	-	Inst Own	8.52%	Short Float	12.28%	Perf Quarter	52.84%
Income	-56.91M	P/S	-	EPS this Y	-	Inst Trans	-2.40%	Short Ratio	3.27	Perf Half Y	-47.07%
Sales	0.00M	P/B	1.21	EPS next Y	-	ROA	-93.10%	Short Interest	8.92M	Perf YTD	-6.47%
Book/sh	0.90	P/C	14.59	EPS next 5Y	-	ROE	-108.18%	52W High	3.70 -70.67%	Perf Year	163.35%
Cash/sh	0.07	P/FCF	-	EPS past 3/5Y	- -	ROIC	-67.45%	52W Low	0.23 367.07%	Perf 3Y	-75.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.50% 12.10%	Perf 5Y	-93.09%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	99.27%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	27.28	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.79	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	27.28	EPS Q/Q	-22.73%	SMA20	9.09%	Beta	-0.03	Target Price	5.50
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	28.03%	Rel Volume	0.90	Prev Close	1.20
Employees	6	LT Debt/Eq	0.00	Earnings	May 14 BMO	SMA200	35.11%	Avg Volume	2.73M	Price	1.09
IPO	Jan 25, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	2,457,576	Change	-9.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-25	Downgrade	Robert W. Baird	Outperform → Neutral	$9 → $1.25
Jan-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$8
Oct-04-21	Initiated	Mizuho	Buy	$6
Jun-04-21	Resumed	Robert W. Baird	Outperform	$5
Jun-29-20	Initiated	Piper Sandler	Overweight	$6
Feb-11-20	Initiated	Robert W. Baird	Outperform	$6
Nov-15-19	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-13-19	Resumed	Raymond James	Outperform
Mar-07-17	Initiated	Ladenburg Thalmann	Buy	$18

May-14-26 07:05AM	Cypherpunk Technologies Reports First Quarter 2026 Financial Results (PR Newswire) +15.38%
Apr-15-26 12:21PM	Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard (PR Newswire) -5.26%
Mar-16-26 04:50PM	Cypherpunk Reports Full Year 2025 Financial Results (PR Newswire) +21.53% +12.60%
Mar-09-26 04:19PM	Zcash Outpaces Bitcoin Gains as Key Development Team Raises $25 Million (decrypt) +5.69%
09:20AM	Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL) (PR Newswire)
07:00AM	Loading…
Jan-22-26 07:00AM	Cypherpunk Adds Arjun Khemani as Strategic Advisor (PR Newswire)
Jan-21-26 02:42AM	Winklevoss Twins Donate $1.4 Million To Support Zcash Network: 'Privacy Is The Next Frontier In Crypto' (Benzinga)
Dec-31-25 11:57AM	David Beckhams Prenetics Ditches Bitcoin Strategy as Santa Rally Fails (CoinDesk) -11.45%
04:50AM	Winklevoss-backed Cypherpunk buys $28 million of zcash, now owns 1.7% of supply (CoinDesk)
Dec-30-25 06:18PM	Is Zcash the Next Corporate Treasury Play? Cypherpunk Now Holds Nearly 2% (Cryptonews) +11.02%
07:00AM	Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC (PR Newswire)
Dec-19-25 07:00AM	Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor (PR Newswire) +39.02%
Dec-10-25 03:51PM	Surveillance is a "Dangerous Experiment" - Zcash Founder Zooko Wilcox on Why Privacy is Actually the Historical Norm (CoinDesk) -11.11%
06:02AM	Winklevoss Twins Double Down on Zcash Hire ZEC Founder Zooko Wilcox as Advisor (CCN)
Dec-09-25 07:00AM	Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor (PR Newswire) +39.66%
07:00AM	Loading…
Nov-18-25 07:00AM	Cypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43% (PR Newswire) +22.22%
Nov-14-25 09:55AM	Cypherpunk Stock Soars on Zcash Rebrand. Should You Buy the Crypto Penny Stock Here? (Barchart) +56.25%
Nov-12-25 06:08PM	Winklevoss-backed stock halted multiple times after wild 550% rally (TheStreet) +368.57% -14.15%
05:07PM	Leap Therapeutics Surges 300% on $50M Winklevoss-Backed Zcash Bet (CoinDesk)
02:00PM	Billionaire twinsbacked stock surges 100% after buying $50M encrypted Bitcoin (TheStreet)
09:50AM	Leap Therapeutics Rebrands as Cypherpunk Technologies to Focus on Zcash (Coinspeaker)
08:00AM	Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results (PR Newswire)
07:01AM	Zcash Treasury Company Launches With Winklevoss Backing (decrypt)
07:00AM	Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy (PR Newswire)
Oct-20-25 07:00AM	Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 (PR Newswire) -5.24%
Oct-09-25 07:00AM	Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire) -8.55%
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) -17.98%
Oct-06-25 10:54AM	Leap Therapeutics Shares Jump on $59M Winklevoss-Led Crypto Deal (CoinDesk) +43.15%
09:00AM	Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire)
Sep-25-25 07:00AM	Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 (PR Newswire) +12.63%
07:00AM	Loading…
Aug-14-25 07:00AM	Leap Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) -28.14%
Jun-23-25 07:00AM	Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives (PR Newswire) -18.04%
May-13-25 07:00AM	Leap Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire) +6.64%
Apr-25-25 01:00PM	Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting (PR Newswire)
Apr-15-25 07:00AM	Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer (PR Newswire) +9.77%
Mar-31-25 01:42PM	Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript (Seeking Alpha)
Mar-26-25 01:29PM	Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer (Benzinga) +16.88%
07:05AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
07:00AM	Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study (PR Newswire)
Jan-28-25 07:00AM	Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study (PR Newswire) -71.11%
Jan-06-25 07:00AM	Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-26-24 07:00AM	Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference (PR Newswire) +5.16%
Nov-13-24 07:00AM	Leap Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire) -7.69%
Sep-30-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Aug-12-24 07:00AM	Leap Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
May-13-24 08:31AM	Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress (GuruFocus.com)
07:00AM	Leap Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-29-24 04:01AM	Pipeline Moves: Investigator-led trial of Lillys merestinib in solid tumours terminated (Clinical Trials Arena) -5.54%
Apr-11-24 08:30AM	Leap Therapeutics Announces $40 Million Private Placement (PR Newswire)
Mar-20-24 09:35AM	Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks (Zacks) +15.91%
Mar-18-24 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Jan-16-24 05:05PM	Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-03-24 07:00AM	Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients (PR Newswire) +12.67%
Dec-11-23 04:05PM	Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +11.28%
Nov-21-23 07:00AM	Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +17.87%
Nov-13-23 07:00AM	Leap Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-03-23 09:55AM	These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird (TipRanks) +26.92%
Sep-05-23 07:00AM	Leap Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-14-23 07:00AM	Leap Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Jul-12-23 07:00AM	Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients (PR Newswire) +6.19%
Jun-20-23 12:30PM	Leap Therapeutics Announces Reverse Stock Split (PR Newswire) -23.22%
Jun-04-23 07:11AM	10 Hot Penny Stocks To Buy (Insider Monkey)
May-25-23 05:10PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) -9.82%
May-15-23 07:00AM	Leap Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-26-23 04:05PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) +6.37%
Apr-12-23 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire) +17.67%
Apr-04-23 11:10AM	Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Mar-24-23 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire)
Mar-17-23 12:26PM	BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate (Benzinga) -16.85%
Mar-16-23 04:05PM	Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 (PR Newswire) +6.05%
Jan-17-23 05:13PM	Leap Therapeutics to acquire Pennsylvania biotech in all-stock deal (American City Business Journals) -14.66%
09:24AM	Leap Therapeutics Shares Fall After Flame Biosciences Acquisition (Benzinga)
08:00AM	Leap Therapeutics Acquires Flame Biosciences (PR Newswire)
Jan-11-23 07:00AM	Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference (PR Newswire)
Nov-21-22 07:00AM	Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-16-22 05:20AM	Leap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021) (Simply Wall St.) -5.12%
Nov-14-22 07:00AM	Leap Therapeutics Reports Third Quarter 2022 Financial Results (PR Newswire) +12.62%
Nov-07-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Oct-26-22 08:19AM	Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-17-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Oct-12-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer (PR Newswire)
Oct-05-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Sep-27-22 08:15AM	Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures (GlobeNewswire)
Sep-07-22 07:00AM	Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference (PR Newswire) +8.02%
Sep-06-22 07:00AM	Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors (PR Newswire) +8.72%
Sep-04-22 06:05PM	Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress (PR Newswire)
Aug-12-22 07:00AM	Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute (PR Newswire)
07:00AM	Leap Therapeutics Reports Second Quarter 2022 Financial Results (PR Newswire)
Jul-21-22 07:47AM	Do Institutions Own Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares? (Simply Wall St.)
Jul-14-22 11:37AM	Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal (Zacks)
11:34AM	Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome (Zacks)
Jul-12-22 11:20AM	Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA (Zacks) -8.80%
11:13AM	Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint (Zacks)
07:00AM	Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer (PR Newswire)
Jul-11-22 11:58AM	Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion (Zacks) -6.72%
06:19AM	Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech (Zacks)
Jul-08-22 11:48AM	Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug (Zacks)

Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. Its novel therapies are designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Chief Investment Officer & DirectorMr. Will McEvoy

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mirabelli Christopher	Director	Mar 26 '26	Sale	0.71	60,000	42,630	130,376	Mar 30 05:29 PM
CHRISTOPHER MIRABELLI	Director	Mar 26 '26	Proposed Sale	0.71	60,000	42,629		Mar 27 09:35 AM
Mirabelli Christopher	Director	Nov 17 '25	Sale	3.14	676,319	2,123,642	2,136	Nov 19 04:06 PM
CAVANAUGH JAMES H	Director	Nov 17 '25	Sale	3.14	261,840	822,178	0	Nov 19 04:05 PM
ONSI DOUGLAS E	CEO,CFO,Pres.,GC,Treas.&Sec.	Nov 17 '25	Sale	3.14	676,319	2,123,642	2,136	Nov 19 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYPH

Cypherpunk Technologies Inc

Upgrade your Finviz experience